{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:51:08Z","timestamp":1793123468119,"version":"4.5.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(Grant No.82260087)"],"award-info":[{"award-number":["(Grant No.82260087)"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Acute ST-segment elevation myocardial infarction (STEMI) remains a serious life threatening event with a poor prognosis due to myocardial ischemia\/reperfusion injury despite coronary revascularization. Extracorporeal cardiac shock wave (ECSW) is a safe, effective and non-invasive new method for the treatment of cardiovascular diseases. The current results show that extracorporeal cardiac shock wave provides a new treatment option for patients with severe and advanced coronary heart disease. However, there are relatively few clinical studies on the application of in vitro cardiac shock waves in patients with myocardial ischemia-reperfusion injury. We hypothesized that extracorporeal cardiac shock therapy would also be effective in reducing clinical endpoints in patients with STEMI reperfusion.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>This study is order to provide a new therapeutic method for patients with myocardial ischemia-reperfusion injury and reveal the possible mechanism of ECSW for ischemia-reperfusion injury.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods and materials<\/jats:title>\n<jats:p>CEECSWIIRI is a single-center, prospective randomized controlled trial that plans to enroll 102 eligible patients with acute ST-segment elevation myocardial infarction reperfusion. Eligible patients with STEMI reperfusion will be randomly divided into external cardiac shock therapy (ECSW) trial group and blank control group. The blank control group will receive optimal drug therapy, and the experimental group will receive optimal drug therapy combined with ECSW. The shock wave treatment plan will be 3-month therapy, specifically 1 week of treatment per month, 3 weeks of rest, 3 times of ECSW in each treatment week, respectively on the first day, the third day and the fifth day of the treatment week, lasting for 3 months and follow-up for 2 years. The primary endpoint will be to assess the 2-year improvement in all-cause death, re-hospitalization due to cardiovascular disease, major unintentional cerebrovascular events, including cardiogenic death, myocardial infarction, heart failure, arrhythmia, emergency coronary revascularization, and stroke in patients with STEMI reperfusion. Secondary endpoints will include improvements in angina pectoris, quality of life, cardiac structure and function, coronary microcirculation, and endothelial progenitor cell-derived miR-140-3p in relation to survival outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>ClinicalTrial.gov.org PRS:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05624203\" xlink:type=\"simple\">NCT05624203<\/jats:ext-link>; Date of registration: November 12, 2022.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0294060","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T18:26:25Z","timestamp":1702059985000},"page":"e0294060","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Principle and design of clinical efficacy observation of extracorporeal cardiac shock wave therapy for patients with myocardial ischemia-reperfusion injury: A prospective randomized controlled trial protocol"],"prefix":"10.1371","volume":"18","author":[{"given":"Xianbin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunke","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifa","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6345-209X","authenticated-orcid":true,"given":"Hongyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"11","key":"pone.0294060.ref001","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion\u2013from mechanism to translation","volume":"17","author":"HK Eltzschig","year":"2011","journal-title":"Nat Med"},{"issue":"5","key":"pone.0294060.ref002","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/heartjnl-2015-307855","article-title":"Reducing myocardial infarct size: challenges and future opportunities","volume":"102","author":"H Bulluck","year":"2016","journal-title":"Heart"},{"issue":"1","key":"pone.0294060.ref003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia-reperfusion injury: a neglected therapeutic target","volume":"123","author":"DJ Hausenloy","year":"2013","journal-title":"J Clin Invest"},{"issue":"12","key":"pone.0294060.ref004","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","article-title":"Myocardial ischaemia-reperfusion injury and cardioprotection in perspective","volume":"17","author":"G Heusch","year":"2020","journal-title":"Nature reviews Cardiology"},{"key":"pone.0294060.ref005","first-page":"1","article-title":"Chinese experts on the treatment of coronary heart disease with Zeta Shock Wave, consensus (2022 edition)","volume":"5","author":"HY He Qing","year":"2022","journal-title":"Chinese Journal of Cardiovascular Disease"},{"issue":"4","key":"pone.0294060.ref006","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MCA.0000000000000577","article-title":"Low-energy cardiac shockwave therapy to suppress left ventricular remodeling in patients with acute myocardial infarction: a first-in-human study","volume":"29","author":"Y Kagaya","year":"2018","journal-title":"Coron Artery Dis"},{"issue":"1S","key":"pone.0294060.ref007","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.chest.2020.03.010","article-title":"Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies","volume":"158","author":"X Wang","year":"2020","journal-title":"Chest"},{"issue":"6","key":"pone.0294060.ref008","first-page":"553","article-title":"Summary of China Cardiovascular Health and Disease Report 2021","volume":"37","author":"Shengshoue Hu","year":"2022","journal-title":"China Recycling Journal"},{"issue":"4","key":"pone.0294060.ref009","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/heartjnl-2020-317165","article-title":"Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China","volume":"107","author":"J Song","year":"2020","journal-title":"Heart"},{"issue":"16","key":"pone.0294060.ref010","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2011.522","article-title":"Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction","volume":"305","author":"SWEDEHEART\/RIKS-HIA","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"pone.0294060.ref011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2018.09.086","article-title":"Multitarget Strategies to Reduce Myocardial Ischemia\/Reperfusion Injury: JACC Review Topic of the Week","volume":"73","author":"SM Davidson","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"pone.0294060.ref012","first-page":"935","article-title":"Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations","volume":"38","author":"DJ Hausenloy","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0294060.ref013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jcb.26169","article-title":"Stem Cell Therapy: A New Therapeutic Option for Cardiovascular Diseases","volume":"119","author":"NH Goradel","year":"2018","journal-title":"J Cell Biochem. J Cell Biochem"},{"issue":"10","key":"pone.0294060.ref014","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","article-title":"Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1\/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy])","volume":"121","author":"J Bartolucci","year":"2017","journal-title":"Circ Res"},{"issue":"30","key":"pone.0294060.ref015","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/eurheartj\/ehv189","article-title":"Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report","volume":"36","author":"P Menasche","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"pone.0294060.ref016","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ccd.21302","article-title":"Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives","volume":"70","author":"MR Ward","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"pone.0294060.ref017","doi-asserted-by":"crossref","first-page":"e000043","DOI":"10.1161\/HCG.0000000000000043","article-title":"Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association","volume":"11","author":"K Musunuru","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"pone.0294060.ref018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4252\/wjsc.v9.i1.9","article-title":"Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology","volume":"9","author":"S Der Sarkissian","year":"2017","journal-title":"World J Stem Cells"},{"issue":"7","key":"pone.0294060.ref019","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCRESAHA.111.253286","article-title":"Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity","volume":"109","author":"S Sahoo","year":"2011","journal-title":"Circ Res"},{"issue":"3","key":"pone.0294060.ref020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.scr.2013.01.002","article-title":"Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K\/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia\/reperfusion injury","volume":"10","author":"F Arslan","year":"2013","journal-title":"Stem Cell Res"},{"key":"pone.0294060.ref021","first-page":"1525","article-title":"Exosome mimetics: a novel class of drug delivery systems","volume":"7","author":"SA Kooijmans","year":"2012","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"pone.0294060.ref022","article-title":"Ischemic Preconditioning Potentiates the Protective Effect of Stem Cells through Secretion of Exosomes by Targeting Mecp2 via miR-22","volume":"9","author":"G Qin","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"pone.0294060.ref023","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/cvr\/cvz209","article-title":"miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy","volume":"116","author":"C Gollmann-Tepekoylu","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"15","key":"pone.0294060.ref024","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2015.02.026","article-title":"Plasma exosomes protect the myocardium from ischemia-reperfusion injury","volume":"65","author":"JM Vicencio","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"pone.0294060.ref025","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/cvr\/cvx118","article-title":"Exosomes secreted by cardiomyocytes subjected to ischaemia promote cardiac angiogenesis","volume":"113","author":"TM Ribeiro-Rodrigues","year":"2017","journal-title":"Cardiovasc Res"},{"issue":"6","key":"pone.0294060.ref026","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3892\/etm.2015.2820","article-title":"Cardiac shockwave therapy improves myocardial function in patients with refractory coronary artery disease by promoting VEGF and IL-8 secretion to mediate the proliferation of endothelial progenitor cells","volume":"10","author":"HY Cai","year":"2015","journal-title":"Exp Ther Med"},{"issue":"7","key":"pone.0294060.ref027","first-page":"3895","article-title":"Extracorporeal cardiac shock waves therapy promotes function of endothelial progenitor cells through PI3K\/AKT and MEK\/ERK signaling pathways","volume":"12","author":"Y Ma","year":"2020","journal-title":"Am J Transl Res"},{"key":"pone.0294060.ref028","doi-asserted-by":"crossref","first-page":"747497","DOI":"10.3389\/fcvm.2021.747497","article-title":"Extracorporeal Cardiac Shock Waves Therapy Improves the Function of Endothelial Progenitor Cells After Hypoxia Injury via Activating PI3K\/Akt\/eNOS Signal Pathway","volume":"8","author":"M Wang","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"pone.0294060.ref029","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1007\/s12350-021-02768-7","article-title":"Efficacy and safety of cardiac shock wave therapy for patients with severe coronary artery disease: A randomized, double-blind control study","volume":"29","author":"N Jia","year":"2021","journal-title":"Journal of Nuclear Cardiology"},{"key":"pone.0294060.ref030","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.664433","article-title":"Cardiac Shock Wave Therapy Ameliorates Myocardial Ischemia in Patients With Chronic Refractory Angina Pectoris: A Randomized Trial","volume":"8","author":"L Weijing","year":"2021","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"pone.0294060.ref031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12947-019-0163-1","article-title":"The effect of cardiac shock wave therapy on myocardial function and perfusion in the randomized, triple-blind, sham-procedure controlled study","volume":"17","author":"J Celutkiene","year":"2019","journal-title":"Cardiovasc Ultrasound"},{"issue":"7","key":"pone.0294060.ref032","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MCA.0000000000000648","article-title":"A randomized, triple-blind trial of cardiac shock-wave therapy on exercise tolerance and symptoms in patients with stable angina pectoris","volume":"29","author":"E Shkolnik","year":"2018","journal-title":"Coronary Artery Disease"},{"key":"pone.0294060.ref033","article-title":"Efficacy of cardiac shock wave therapy in patients with stable angina: The design of randomized, triple blind, sham-procedure controlled study","author":"E Shkolnik","year":"2018","journal-title":"The Anatolian Journal of Cardiology"},{"issue":"15","key":"pone.0294060.ref034","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/jama.2013.3527","article-title":"Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial","volume":"309","author":"B Assmus","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"pone.0294060.ref035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1751-7133.2010.00182.x","article-title":"Initial Clinical Experience With Extracorporeal Shock Wave Therapy in Treatment of Ischemic Heart Failure","volume":"16","author":"YA Vasyuk","year":"2010","journal-title":"Congestive Heart Failure"},{"issue":"02","key":"pone.0294060.ref036","first-page":"141","article-title":"Preliminary observation of extracorporeal cardiac shock wave in treatment of ischemic heart failure","author":"GT Peng Yunzhu","year":"2012","journal-title":"Chinese Journal of Cardiovascular Disease"},{"issue":"4","key":"pone.0294060.ref037","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1074248415616189","article-title":"Clinical Effect of Cardiac Shock Wave Therapy on Myocardial Ischemia in Patients With Ischemic Heart Failure","volume":"21","author":"W Wang","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"pone.0294060.ref038","doi-asserted-by":"crossref","first-page":"779936","DOI":"10.3389\/fcell.2021.779936","article-title":"Extracorporeal Cardiac Shock Wave-Induced Exosome Derived From Endothelial Colony-Forming Cells Carrying miR-140-3p Alleviate Cardiomyocyte Hypoxia\/Reoxygenation Injury via the PTEN\/PI3K\/AKT Pathway","volume":"9","author":"D Yang","year":"2021","journal-title":"Front Cell Dev Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T18:26:50Z","timestamp":1702060010000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294060"}},"subtitle":[],"editor":[{"given":"Kamal","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294060","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}